Zacks Investment Research Lowers Jounce Therapeutics (JNCE) to Hold
Zacks Investment Research lowered shares of Jounce Therapeutics (NASDAQ:JNCE) from a buy rating to a hold rating in a report issued on Saturday.
According to Zacks, “Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company’s lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells found in a range of solid tumors. It also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. Jounce Therapeutics, Inc. is based in Cambridge, United States. “
Several other equities analysts also recently commented on JNCE. Cowen reaffirmed a hold rating on shares of Jounce Therapeutics in a research note on Tuesday, November 13th. Raymond James lowered their price objective on shares of Jounce Therapeutics from $13.00 to $12.00 and set an outperform rating for the company in a research note on Tuesday, October 23rd. ValuEngine raised shares of Jounce Therapeutics from a sell rating to a hold rating in a research note on Thursday, August 2nd. HC Wainwright set a $13.00 price objective on shares of Jounce Therapeutics and gave the company a buy rating in a research note on Wednesday, November 14th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Jounce Therapeutics from $12.00 to $10.00 and set a hold rating for the company in a research note on Friday, August 10th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of $11.92.
Jounce Therapeutics (NASDAQ:JNCE) last posted its quarterly earnings results on Tuesday, November 13th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.11. The business had revenue of $14.53 million during the quarter, compared to the consensus estimate of $12.80 million. Jounce Therapeutics had a negative net margin of 59.74% and a negative return on equity of 29.58%. On average, equities analysts anticipate that Jounce Therapeutics will post -1.16 EPS for the current fiscal year.
Large investors have recently modified their holdings of the company. NumerixS Investment Technologies Inc bought a new position in Jounce Therapeutics in the second quarter worth about $132,000. Creative Planning bought a new position in Jounce Therapeutics in the third quarter worth about $143,000. Bank of America Corp DE raised its stake in Jounce Therapeutics by 243.4% in the second quarter. Bank of America Corp DE now owns 28,607 shares of the company’s stock worth $219,000 after buying an additional 20,276 shares in the last quarter. Trexquant Investment LP bought a new position in Jounce Therapeutics in the third quarter worth about $216,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in Jounce Therapeutics in the third quarter worth about $231,000. 84.24% of the stock is owned by hedge funds and other institutional investors.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.
Read More: How do candlesticks reflect price movement?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.